The Impact of Patient Positioning and Use of Belly Board on Small Bowel and Urinary Bladder Volume Irradiated in Patients Receiving Radiotherapy for Rectal Cancer: A Prospective Phase II Study
Launched by TEL-AVIV SOURASKY MEDICAL CENTER · Jun 10, 2010
Trial Information
Current as of August 02, 2025
Unknown status
Keywords
ClinConnect Summary
This is a prospective non-randomized open study to evaluate the impact of patient's positioning and use of belly board in rectal radiotherapy.
In contrast to previous studies, the clinical target volume and organ at risk will be contouring for three-dimensional planning. With the aid of modern imaging, correlation can be obtained between dose and volume (DVH) since both parameters have an impact on organ tolerance to ionizing radiation.
Thirty patients with rectal cancer scheduled to receive "rectal radiotherapy", pre or postoperative will be included (15 patients from each group).
In ad...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients with rectal cancer scheduled to receive "rectal radiotherapy", pre or postoperative
- Exclusion Criteria:
- • No exclusion
About Tel Aviv Sourasky Medical Center
Tel Aviv Sourasky Medical Center, a leading academic medical institution in Israel, is renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a multidisciplinary approach, the center integrates cutting-edge medical technology and evidence-based practices to enhance patient care and outcomes. Its robust infrastructure supports a diverse range of clinical studies, fostering collaboration among healthcare professionals, researchers, and industry partners. The center's dedication to research excellence and patient safety positions it as a key player in the global clinical research landscape, driving advancements in medical knowledge and treatment options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tel Aviv, , Israel
Patients applied
Trial Officials
Eliahu Gez, MD
Principal Investigator
TASMC
Elaihu Gez, MD
Study Chair
TASMC
Eliahu Gez, MD
Study Chair
TASMC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials